Rapport

• Gabet, A., Bertrand, M., Jabagi, M. J., Kolla, E., Olié, V., & Zureik, M. (2025). Sécurité maternelle et fœtale de la  vaccination par Abrysvo® pendant la grossesse : Étude observationnelle nationale en France lors de la première campagne de vaccination 2024–2025 13 novembre 2025. [lien]

Articles publiés dans des revues à Comité de lecture

• Tréluyer, L., Bertrand, M., Gabet, A., Jabagi, M.-J., Kolla, E., Olié, V., Zureik, M., & Rachas, A. (2026). Dual Immunization Against RSV With RSVpreF and Nirsevimab. JAMA Pediatrics. [lien]
• Gabet, A., Bertrand, M., Jabagi, M.-J., Kolla, E., Olié, V., & Zureik, M. (2025). Maternal and Neonatal Outcomes After Respiratory Syncytial Virus Prefusion F Protein Vaccination During Pregnancy : Analysis From the 2024–2025 Immunization Campaign in France. Obstetrics & Gynecology, 10.1097/AOG.0000000000006121. [lien]
• Jabagi, M. J., Cohen, J., Bertrand, M., Chalumeau, M., & Zureik, M. (2025). Nirsevimab Effectiveness at Preventing RSV-Related Hospitalization in Infants. NEJM Evidence, 4(3), EVIDoa2400275. [lien]
• Jabagi, M.-J., Bertrand, M., Gabet, A., Kolla, E., Olié, V., & Zureik, M. (2025). Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus–Related Hospitalization in Newborns. JAMA. [lien]
• Vegas, L. P., Drouin, J., Weill, A., & Dray-Spira, R. (2024). Pregnancy outcomes in women with rheumatoid arthritis : An 11-year French nationwide study. RMD Open, 10(1), e003762. [lien]
• Meyer, A., Miranda, S., Drouin, J., Weill, A., Carbonnel, F., & Dray-Spira, R. (2024). Safety of vedolizumab and ustekinumab compared with anti-TNF in pregnant women with inflammatory bowel disease. Clinical Gastroenterology and Hepatology. [lien]
• Lassalle, M., Zureik, M., & Dray-Spira, R. (2023). Proton Pump Inhibitor Use and Risk of Serious Infections in Young Children. JAMA Pediatrics, 177(10), 1028‑1038. [lien]
• Meyer, A., Rios, P., Drouin, J., Weill, A., Carbonnel, F., & Dray-Spira, R. (2023). Maternal exposure to anti-TNF or thiopurines for IBD does not increase risk of early-life malignancy in children. Clinical Gastroenterology and Hepatology, 21(10), 2679‑2681. [lien]
• Meyer, A., Neumann, A., Drouin, J., Weill, A., Carbonnel, F., & Dray-Spira, R. (2022). Benefits and Risks Associated With Continuation of Anti–Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease : A Nationwide Emulation Trial. Annals of Internal Medicine, 175(10), 1374‑1382. (world). [lien]
• Meyer, A., Taine, M., Drouin, J., Weill, A., Carbonnel, F., & Dray-Spira, R. (2022). Serious Infections in Children Born to Mothers With Inflammatory Bowel Disease With In Utero Exposure to Thiopurines and Anti-Tumor Necrosis Factor. Clinical Gastroenterology and Hepatology, 20(6), 1269-1281.e9. [lien]
• Meyer, A., Drouin, J., Weill, A., Carbonnel, F., & Dray-Spira, R. (2021). Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF : A French nationwide study 2010–2018. Alimentary Pharmacology & Therapeutics, 54(3), 302‑311. [lien]
• Meyer, A., Drouin, J., Weill, A., Carbonnel, F., & Dray‐Spira, R. (2020). Pregnancy in women with inflammatory bowel disease : A French nationwide study 2010-2018. Alimentary Pharmacology & Therapeutics, 52(9), 1480‑1490. [lien]